Page last updated: 2024-09-04

lonafarnib and erlotinib hydrochloride

lonafarnib has been researched along with erlotinib hydrochloride in 2 studies

Compound Research Comparison

Studies (lonafarnib)	Trials (lonafarnib)	Recent Studies (post-2010) (lonafarnib)	Studies (erlotinib hydrochloride)	Trials (erlotinib hydrochloride)	Recent Studies (post-2010) (erlotinib hydrochloride)
224	34	90	4,353	786	3,033

Protein Interaction Comparison

Protein	Taxonomy	erlotinib hydrochloride (IC50)
Epidermal growth factor receptor	Homo sapiens (human)	0.1683
Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)	1.705
Serine/threonine-protein kinase B-raf	Mus musculus (house mouse)	0.04

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kurisu, K; Okamura, T	1
Bernhard, JC; Ferrière, JM; Ravaud, A; Robert, G; Wallerand, H	1

Reviews

2 review(s) available for lonafarnib and erlotinib hydrochloride

Article	Year
[Molecular targeted therapy for malignant brain tumors]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 9 Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Piperidines; Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2005
[Targeted therapy for locally advanced and/or metastatic bladder cancer]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18, Issue:7 Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Immunosuppressive Agents; Mutation; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Targeted Gene Repair; Trastuzumab; Urinary Bladder Neoplasms	2008

Article

Year

[Molecular targeted therapy for malignant brain tumors].

Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 9

Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Piperidines; Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2005

[Targeted therapy for locally advanced and/or metastatic bladder cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18, Issue:7

Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Immunosuppressive Agents; Mutation; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Targeted Gene Repair; Trastuzumab; Urinary Bladder Neoplasms

2008